Point72 Hong Kong Ltd Invests $764,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Point72 Hong Kong Ltd acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 9,520 shares of the medical equipment provider's stock, valued at approximately $764,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Lantheus by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock valued at $458,271,000 after purchasing an additional 389,828 shares during the period. Farallon Capital Management LLC boosted its stake in shares of Lantheus by 53.7% in the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider's stock worth $182,999,000 after acquiring an additional 796,000 shares during the period. Westfield Capital Management Co. LP grew its position in shares of Lantheus by 25.3% during the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider's stock worth $121,867,000 after purchasing an additional 394,837 shares in the last quarter. Reinhart Partners LLC. raised its stake in Lantheus by 8.4% during the 1st quarter. Reinhart Partners LLC. now owns 1,470,383 shares of the medical equipment provider's stock valued at $91,517,000 after purchasing an additional 114,110 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Lantheus by 1.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider's stock worth $99,525,000 after purchasing an additional 19,071 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. JMP Securities reduced their price objective on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 1st. Truist Financial cut their target price on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. Leerink Partners raised their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a report on Thursday, July 11th. Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price for the company. Finally, B. Riley lifted their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.

Lantheus Trading Up 2.8 %

NASDAQ LNTH traded up $2.93 on Friday, hitting $107.36. 662,393 shares of the stock were exchanged, compared to its average volume of 1,012,184. The firm has a market capitalization of $7.44 billion, a P/E ratio of 15.94 and a beta of 0.50. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The stock has a fifty day moving average price of $104.64 and a two-hundred day moving average price of $85.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). The company had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The firm's revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.40 earnings per share. Research analysts forecast that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Insider Activity at Lantheus

In related news, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Lantheus news, CAO Andrea Sabens sold 341 shares of the business's stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the completion of the transaction, the chief accounting officer now directly owns 62,216 shares in the company, valued at $7,661,900.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gerard Ber sold 15,500 shares of the business's stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company's stock, valued at $2,047,402.08. The disclosure for this sale can be found here. Insiders sold 40,852 shares of company stock worth $3,922,001 over the last three months. 1.50% of the stock is owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.